Exhibit 99.1




FOR IMMEDIATE RELEASE


AMGEN AND HYSEQ PHARMACEUTICALS TO COLLABORATE ON NOVEL ACTING THROMBOLYTIC


THOUSAND OAKS, Calif. and SUNNYVALE, Calif., January 9, 2002 -Amgen (Nasdaq:
AMGN) and Hyseq Pharmaceuticals (Nasdaq: HYSQ) today announced that the
companies have entered into a collaboration to develop and commercialize
alfimeprase, a novel acting thrombolytic, for the treatment of peripheral
arterial occlusions and other cardiovascular indications.

Under the terms of the agreement, Hyseq will lead development and be responsible
for all clinical development activities and Amgen will be responsible for
manufacturing activities. Amgen will have the option to lead commercialization
efforts in which both companies may participate.

As part of the transaction, Hyseq granted Amgen warrants to purchase Hyseq
common stock at a premium to the current market price. No additional financial
terms were disclosed.

Alfimeprase, a product candidate that was identified through Amgen's research
program, is a derivative of the fibrolase enzyme and is being developed for the
treatment of peripheral arterial occlusions (PAO). PAO of the lower extremity is
a significant cause of morbidity and amputation in the United States with over
100,000 cases reported annually. Pre-clinical studies indicate that alfimeprase
is a promising agent for dissolving clots (clot lysis), and may be particularly
well suited for the PAO indication. An Investigational New Drug (IND)
application for alfimeprase has been filed, and Hyseq anticipates initiating
clinical studies as soon as possible.

"We have studied the characteristics of Alfimeprase and believe it may offer
significant benefits to patients," said Roger Perlmutter, Amgen's Executive Vice
President, Research and Development. "Hyseq's management and development team
has experience in developing thrombolytics for cardiovascular disease, and
therefore is uniquely positioned to optimally develop this product candidate.
Hyseq has our full confidence to lead the development program."

"We are especially pleased with the opportunity to collaborate with Amgen on
this clinical product candidate that we feel we can develop to its full
potential," said Ted W. Love, M.D., President and CEO of Hyseq Pharmaceuticals.
"While we remain committed to developing therapeutics from our proprietary full
length gene sequences,

we are excited with the opportunity to develop a product that is ready for
clinical trials and targets an unmet medical need."

Hyseq Pharmaceuticals, Inc. is engaged in the research and development of
biopharmaceutical products based upon its proprietary database of full-length
human gene sequences. Hyseq's screening-by-hybridization platform provided a
significant advantage in the discovery of novel, rarely expressed genes, and
assembly of one of the most important proprietary databases of full-length human
gene sequences. Hyseq is expanding and accelerating its research activities to
further elucidate the role of novel genes in its proprietary database for the
development and commercialization of biotherapeutic products. Information about
Hyseq is available at www.hyseq.com [http://www.hyseq.com] or by phoning (408)
524-8100.

Amgen is a global biotechnology company that discovers, develops, manufactures
and markets important human therapeutics based on advances in cellular and
molecular biology.

This news release contains forward-looking statements that involve significant
risks and uncertainties, including those discussed below and more fully
described in the Securities and Exchange Commission reports filed by Amgen,
including Amgen's most recent Form 10-Q. Amgen conducts research in the
biotechnology/pharmaceutical field where movement from concept to product is
uncertain; consequently, there can be no guarantee that any particular product
candidate will be successful and become a commercial product.

Furthermore, Amgen's research, testing, pricing, marketing and other operations
are subject to extensive regulation by domestic and foreign government
regulatory authorities. In addition, sales of Amgen's products are affected by
reimbursement policies imposed by third party payors, including governments,
private insurance plans and managed care providers. These government regulations
and reimbursement policies may affect the development, usage and pricing of our
products.

In addition, while Amgen routinely obtains patents for products and technology,
the protection offered by our patents and patent applications may be challenged,
invalidated or circumvented by competitors.

Because forward-looking statements involve risks and uncertainties, actual
results may differ materially from current results expected by Amgen. Amgen is
providing this information as of January 9, 2002, and expressly disclaims any
duty to update information contained in this press release.

This press release also contains forward-looking statements concerning Hyseq
Pharmaceuticals. Statements included in this press release which are not
historical in nature, are intended to be, and are hereby identified as
"forward-looking statements" for purposes of the safe harbor provided by the
Private Securities Litigation Reform Act of 1995. Forward looking statements may
be identified by words such as "believe,"

"expect," "anticipate," "should," "may," "estimated" and "potential," among
others. Hyseq cautions readers that forward-looking statements, including
without limitation, those relating to the Hyseq's future business prospects are
subject to certain risks and uncertainties that could cause actual results to
differ materially from those indicated in the forward-looking statements. For a
discussion of factors that may cause results to differ, see Hyseq's reports
filed with the SEC, including its Annual Report on Form 10-K for the year ended
December 31, 2000. Hyseq disclaims any intent or obligation to update these
forward-looking statements.

CONTACTS:

         AMGEN
Jeff Richardson,  805/447-3227 (media)
         Cary Rosansky, 805/447-4634 (investors)

         HYSEQ PHARMACEUTICALS
Peter S. Garcia, 408/746-4574 (media and investors)

# # #